- Findings to be shared from a study analyzing real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) who received trifluridine and tipiracil (FTD/TPI) monotherapy or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy
- Additional analysis of the same dataset to be shared on real-world clinical outcomes in 639 black patients with mCRC
, /PRNewswire/ — Taiho Oncology, Inc. announced today presentations at the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), to be held Jan. 23-25, 2025, in San Francisco. The poster presentations include a comparison of real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) who received trifluridine and tipiracil (FTD/TPI) monotherapy or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy and an additional analysis of the same dataset on real-world clinical outcomes in 639 black patients with mCRC.
“Access to real-world clinical outcomes of FTD/TPI monotherapy versus FTD/TPI+bev combination therapy among patients with mCRC, could provide valuable insights to ultimately help improve clinical development and treatment …